Our commitment to corporate governance underpins the trust that our investors, employees and institutions have in us. We maintain our efforts to build confidence as we continue to grow.

Management Board

Valneva’s Management Board is a highly dedicated international team, with diverse backgrounds, experience, expertise and skills.

Thomas Lingelbach President & Chief Executive Officer

Previous CEO of Intercell, Managing Director for Novartis Vaccines & Diagnostics Germany, Vice President of Global Industrial Operations at Chiron Vaccines, more than 25 years in the vaccine industry.

Franck Grimaud President & Chief Business Officer

Previous CEO and co-founder of Vivalis, formerly responsible for Groupe Grimaud’s development in Asia, 25 years in corporate business development and life sciences.

Juan Carlos Jaramillo, MD Chief Medical Officer

Senior international positions in various Pharmaceutical/ Biotech organizations, including GlaxoSmithKline, Celsion, Grünenthal and Daiichi Sankyo, strong expertise in Medical Affairs and Clinical Development, as well as Global Market Access, 20 years of experience in life sciences.

Frederic Jacotot General Counsel and Corporate Secretary

VP Legal & IP and General Counsel of Valneva since September 2013, former Division Counsel at Abbott, 30 years as a legal expert in the pharmaceutical industry.

Supervisory Board

As part of Valneva’s corporate governance system, the Supervisory Board, acting in the interests of the shareholders, participates actively in reviewing the Company’s strategic options and setting direction together with the Management Board.

Frédéric Grimaud (F)

Chairman of Valneva’s Supervisory Board, Representative of the Company's largest shareholder, President and CEO of Groupe Grimaud.

James Sulat (U.S.)

Member of the Supervisory Board & Chair - Audit Committee, Former CFO for Chiron and CEO of Maxygen.

Anne-Marie Graffin (F)

Member of the Supervisory Board, Managing Director of SMAG Consulting, Supervisory Board member of Nanobiotix SA, Board member of Sartorius Stedim Biotech SA, Former Vice President at Sanofi Pasteur MSD.

Thomas Casdagli (UK)

Member of the Supervisory Board, Partner at MVM Partners LLP, Qualified as chartered accountant with PWC’s Private Equity and Venture Capital practice. Board member of eZono AG, Onbone Oy and Patient Connect Ltd.

Sharon Tetlow (U.S.)

Member of the Supervisory Board, Founder and Managing Partner of Potrero Hill Advisors, Member of the Board of Directors and Audit Committee Chair of Catalyst Biosciences (NASDAQ:CBIO).

Johanna Willemina Pattenier (CH)

Member of the Supervisory Board, Former General Manager of Novartis Vaccines and Diagnostics in Basel (now a GlaxoSmithKline company) and GSK / Novartis vaccines integration lead. Previously held various commercial and medical roles at GSK, Organon and Byk Gulden.

Scientific Advisory Board

Valneva announced the formation of a Scientific Advisory Board (SAB) as part of the evolution of its governance structure in July 2019.

Dr. Ralf Clemens, MD, Ph.D. Chair

Member of Board of Trustees International Vaccine Institute IVI, member GHIT scientific selection committee, Advisor Bill & Melinda Gates Foundation, former Head/Senior Vice President Vaccine Development at GSK, Novartis and Takeda

Dr. Norman W. Baylor, Ph.D.

President and CEO of Biologics Consulting, Temporary Advisor to the World Health Organization; Former Director of the US FDA Office of Vaccines Research and Review; Former FDA Liaison to the Centers for Disease Control’s Advisory Committee on Immunization Practices

Dr. Anna Durbin, MD

Professor of International Health at the Johns Hopkins Bloomberg School of Public Health, Principal Investigator at the Center for Immunization Research

Dr. Alain Munoz, MD, Ph.D.

Board member of Amryt Pharma, Supervisory Board member of OxThera AB, Zealand Pharma A/S, former SVP for international development at Sanofi, former SVP of the pharmaceutical division at Fournier Laboratories

Dr. George R. Siber, MD, PhD

Adjunct Professor of Medicine at Johns Hopkins University, Co-founder and Board Member of Affinivax, Board Member of Genocea, former Supervisory Board Member of Crucell and former Executive Vice President and CSO of Wyeth Vaccines

Dr. Stanley Plotkin, MD

Emeritus Professor, Wistar Institute, University of Pennsylvania, Former director of the division of infectious diseases at Children’s Hospital of Philadelphia, associate Chairman of the department of pediatrics at the University of Pennsylvania and Medical Director at Sanofi Pasteur

Alexander von Gabain

Chairman of the trans-European innovation consortium EITHealth, Former Vice-President of the Karolinska Institute, Co-founder of Intercell.